Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Open evidence library

Search the archive.

Current and older evidence is free during beta. Sign in for unlimited card access and full source downloads.

Matching cards
2022 Michigan Negative
Turns › IPR Bad › 1NC---IPR Bad---Warming

IPR trades off with effective green technology- that’s key to solve climate change.

Jinkai Lee 20, Center for Energy, Environment and Economy Research, Zhengzhou University, “DOES INTELLECTUAL PROPERTY RIGHTS PROTECTION CONSTITUTE A BARRIER TO RENEWABLE ENERGY? AN ECONOMETRIC ANALYSIS”, Cambridge University Press: National Institute Economic Review , Volume 251 , February 2020 , pp. R37 - R46, 2-5-2020, https://www.cambridge.org/core/journals/national-institute-economic-review/article/abs/does-intellectual-property-rights-protection-constitute-a-barrier-to-renewable-energy-an-econometric-analysis/4A4BE835821D05BFCC2BCD055A006544)/maze

The debates on the impact of intellectual property rights has been extended to the current discussion on climate change mitigation. Mass development, transfer and adoption of climate-friendly technologies and renewable energy has been recognised as essential to mitigating climate change within the required timeframe (Copenhagen Economics, 2009). The share of renewable energy in global energy use rose from 17 per cent in 1990 to 18 per cent in 2015 (figure 1), but a large proportion of this renewable energy is from traditional biomass. Considerable efforts are required to develop and adopt key technologies such as solar and wind. However, given the differences in resource endowment, economic development level and technological advancement among countries, there is need for technology and know-how transfer from technologically-advanced countries to technologically lagging countries (Ockwell et al., 2010). Technology transfer is crucial given the asymmetry in research and development expenditure between developed and developing countries as shown in figure 2. According to Correa (2013), 90 per cent of technological development is concentrated in the United States, European Union, Japan and China; and 80 per cent of all patented innovations in carbon capture, geothermal, solar PV and wind energy technologies are owned by companies from France, Germany, Japan, South Korea, United Kingdom and the United States. The TRIPS Agreement acknowledges these differences by taking into consideration “the developmental and technological objectives” of its members, while also recognising the special needs of its least-developed country (LDC) members (preamble TRIPS Agreement). The TRIPS Agreement grants their least developed country members more flexibility in the implementation of their obligation under TRIPS in order to help them achieve a strong technological base. This flexibility is not available to non-members of least developing countries. The issue of intellectual property rights is a major point of discussion in innovation and technology transfer, including clean energy technology innovation and transfer. According to Latif (2012, 2013), technology transfer and innovation are key issues in the Rio+20 United Nations Conference on Sustainable Development discussions, but IPR which are related to them are barely mentioned. Nonetheless, there has been considerable policy debate over the scope and role of IPR protection with respect to clean energy and climate mitigation technologies. Some studies argue that IPR protection serves as an incentive to innovate and transfer clean energy technologies, while others claim that IPR protection would lead to higher costs of clean technology and hinder developing countries’ access because of the exclusive rights of the patent holder (ICTSD, 2008; Kapur, 2011). Although the TRIPS Agreement provides for exceptions to the exclusive right of patent holders under its Article 30, these exceptions apply collectively and are limited in nature. The Agreement also addresses the abuse of intellectual property rights by its holders, by providing that appropriate steps could be taken where IPR would unreasonably restrain trade or affect technology transfer (Article 8(2) TRIPS Agreement) The studies that examine the effect of IPR on climate change and clean energy technology have mixed conclusions (Hascic et al., 2010; UNEP, et al., 2010), partly because of inadequate data, different data sources and different methodologies. The analysis of the impact of IPR protection on clean technology innovation and transfer is a relatively young field of research. The majority of studies approach the subject mainly from theoretical, legal and case studies perspectives (Kapur, 2011; IRENA, 2012; Copenhagen Economics, 2009). To date, the literature lacks a comprehensive empirical investigation of the impact of IPR protection on renewable energy using econometric methods. This study makes an important contribution to the literature on renewable energy development. While most studies on renewable energy development and adoption have focused extensively on the technical and economic aspects, little is known about the legal and institutional frameworks that may influence renewable energy development. This study explores legal and institutional frameworks with respect to renewable energy and focuses specifically on IPR protection. While previous studies on the subject have developed theoretical or case study approaches, this study extends the IPR-renewable energy literature by taking advantage of novel panel data on the degree of IPR protection – the GinartePark Index – and adopting fixed effect panel regression techniques. This broadens the existing literature by using econometrics techniques to analyse the effect of intellectual property rights protection on climate-related technologies/renewable energy use. The two main research questions in the study are as follows: does IPR protection hinder renewable energy development? Does reforming IPR systems have significant positive impacts on renewable energy development?

2022 Michigan Negative
Turns › IPR Bad › 1NC---IPR Bad---Generic

Patent system often stifles the innovation it was designed to encourage.

Freilich and Meurer, 21 [Michael J. Meurer is a Professor of Law, Boston University, Janet Freilich is a Associate Professor of Law, Fordham University, 3-16-2021, accessed on 7-18-2022, The Conversation, "Patent system often stifles the innovation it was designed to encourage", https://theconversation.com/patent-system-often-stifles-the-innovation-it-was-designed-to-encourage-148075]/ISEE

Over his career Thomas Edison garnered more U.S. patents than anyone in his time. Edison profited from his patents, but he was also exposed to the dark side of the patent system. He had to contend with lawsuits by other patentees who sought – and sometimes won – a piece of his success. While the patent system is designed to spur innovation like Edison’s, it also hampers it. Easy copying and imitation discourage innovation, because why make the effort if someone else will profit from it? The patent system works by enabling inventors to block unauthorized use of patented technology. Most technologies are developed by many inventors over many years, a process called “cumulative” innovation. Too often, however, early inventors get a patent on a small and perhaps insignificant piece of the technological puzzle, yet their patent covers the entire puzzle. Inventors who solve subsequent parts of the puzzle may need to pay royalties to the patentee, even if their contributions are larger. As legal experts who focus on technology law and policy, we suggest that the problem boils down to two issues: too many patents and too little accurate information about them. The U.S. is awash in patents. Over 350,000 U.S. patents were granted in 2019, four times the per capita rate in 1980. From the perspective of research managers at big firms, patents are cheap and easy to get. For example, in the early 2000s Bill Gates decided that Microsoft was patent-poor, and within a few years the company increased annual patent applications by 50%. Patents are easy to get because the standards of patentability are low and because the burden is on the U.S. Patent and Trademark Office to prove an invention is not patentable. Patent examination is slow. It often takes three years or more. Despite increased staffing, the backlog of patent applications has continued to grow, and examiners spend on average only 20 hours reviewing each application. The patent examiner is required to read and understand the invention in an application, determine whether the invention meets the claims of the application, search existing technology to see if the invention already exists and write a response to the application. Helter-skelter examination causes errors – many patents are too broad, or they cover obvious inventions. To draw attention to problems caused by the flood of low-quality patents, billionaire entrepreneur Mark Cuban endowed a chair at the Electronic Frontier Foundation dedicated to elimination of “stupid patents.” Innovative firms that succeed in assembling many pieces of a technology puzzle into a finished product must consult with a patent lawyer to learn whether their new technology is covered by one or more patents owned by others. Ideally an innovator will get permission to use patented technology, usually for a fee, or redesign its technology to steer clear of relevant patents. In practice this patent “clearance” process is difficult, costly and sometimes impossible. For technologies like smartphones, a patent attorney likely would need to review hundreds of patents, including many patents that are not granted until long after the new product is launched. Failure to license relevant patents creates a risk of litigation and the threat the new technology could be forced out of the marketplace. As a result, smartphone patent litigation is far too common. Apple – a smartphone pioneer – has participated in scores of lawsuits around the globe as both a defendant and plaintiff. As a plaintiff, Apple sometimes uses its patents opportunistically to hinder innovation by its rivals. For example, Apple sued Samsung using a patent that claimed the slide-to-unlock feature on a phone as Apple’s invention. Despite strong evidence that inventors before Apple had already accomplished the key steps to implement this feature, Apple convinced the courts that their version of this feature was patentable, and after seven years Samsung agreed to pay license fees to Apple to settle the case. Economic research suggests that these litigation costs and license fees burden innovative firms to such a degree that on balance the patent system discourages innovation. In other words, innovative firms gain a benefit from their patents on their new technology, but that benefit is more than offset by the many patents owned by others that might be asserted against the new technology. When an inventor gets a patent, she is supposed to reveal the secret sauce behind the invention in the patent, a public document. This allows scientists and engineers to learn about the invention and use that information to improve the technology. Or at least, that’s the theory. In practice, many inventors make shoddy disclosures. Experiments reported in patents are sometimes fictional and often rely on dubious methodology. For instance, patent law permits an inventor to disclose the fictional finding that a drug treats cancer as evidence that she deserves a patent on that drug. Inventors applying for patents are allowed to include predicted experimental results. The intent is to allow for earlier disclosure and to help smaller companies secure funding. But when evidence in patents is wrong, other innovators can be misled. Further, if other innovators want to figure out if the patented drug really treats cancer – or any other disease – they need a license from the patentee. Sometimes key pieces of evidence are missing entirely from patents. This happens when a patent covers aspects of a technology that the patentee didn’t actually invent. Imagine discovering that paper is a mediocre incandescent conductor in light bulbs and using that discovery to get a patent covering thousands of other conductors, including ones that, unbeknownst to you, work much better. Later innovators might want to figure out whether other substances are better conductors than paper, but they can’t even start experiments without a license. This happened to Edison. He was sued for patent infringement after discovering a far better conductor than that discovered by the patentee – but because the patent was written broadly, it nevertheless covered Edison’s invention. There is also too little information about the boundaries of patents. When an inventor gets a patent, she is also supposed to provide clear boundary information – what a patent application covers and what it doesn’t – to the public about her patent rights. The patent system fails to ensure this, however. The boundary information in patent applications is hidden for 18 months until the application is published, and even longer if the boundaries change later during examination. Once the patent is granted, lawyers, judges and the public often have difficulty reaching agreement on the meaning of boundary language that may be intentionally vague or ambiguous. Inventors who come up with new chemicals, including pharmaceuticals, tend to benefit from the patent system. Unfortunately, the system appears to impose a net cost on most other technologies, especially in high-tech industries. Opportunistic patent owners, often called patent trolls, surprise inventors with patent claims about inventions that are minor or distantly related to the technology that is the target of the suit. Economics research shows such trolling activity slows innovation. [Over 100,000 readers rely on The Conversation’s newsletter to understand the world. Sign up today.] The patent system can be improved to deliver a net gain to all inventors even without being drastically reworked. A good start would be to rigorously enforce existing standards about information disclosure. Courts should push inventors to clearly describe and explain their inventions. The flood of patents on minor technical advances could be ended if patent fees were increased and if the nonobviousness standard, which screens out minor advances, was made stronger. Reducing the number of patents and increasing the amount of information about each patent would go a long way toward making the patent system work the way it was intended.

2022 Michigan Negative
Turns › IPR Bad › 2NC---IPR Bad---Disease

IP protections are vital to resolve vaccine deficiencies. History disproves all pro patent arguments

Kumar, PhD, 7-12-21 (Rajeesh, Associate Fellow Manohar Parrikar Institute for Defence Studies and Analysis, https://www.idsa.in/issuebrief/wto-trips-waiver-covid-vaccine-rkumar-120721)

In October 2020, India and South Africa had submitted a proposal to the World Trade Organization (WTO), suggesting a waiver of certain provisions of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement for the “prevention, containment and treatment of COVID-19”. The proposal seeks the waiver of “the implementation, application, and enforcement of sections 1, 4, 5 and 7 of part II of the TRIPS agreement”, which are stipulations referring to copyright, industrial design, patents, and undisclosed information (trade secrets).1 The proponents of the proposal argue that a waiver will enable timely and equitable access to affordable health products and technologies, including vaccines. Though many member countries had supported and co-sponsored the proposal, a small but influential group of countries, mainly Australia, Canada, the European Union (EU), Japan, the United Kingdom (UK) and the United States (US), opposed it. They argued that existing exceptions under the TRIPS Agreement are sufficient to address the concerns mentioned in the proposal. This resulted in sidelining of the waiver proposal for months. However, on 5 May 2021, the Joseph Biden administration announced its support for waiving intellectual property protections for COVID-19 vaccines.2 It was a significant step towards breaking the seven-month gridlock, and led to many more countries modifying their position on the waiver proposal. On 25 May 2021, the co-sponsors of the waiver proposal submitted a revised proposal that specified the scope of the waiver as applying to “health products and technologies” and also added a section on the proposed duration of the waiver, i.e., three years.3 At present, more than 100 countries, including the US and China support this proposal. The principal opponent of the waiver is the EU and in June 2021, it submitted an alternative proposal to the TRIPS Council, which requested to keep TRIPS’ provisions intact and focused on compulsory licensing and removing vaccine export restrictions to address the concerns raised by India and South Africa.4 The EU proposal also stated that the TRIPS Agreement does not prevent countries from taking measures to protect public health.5 At the meeting of the TRIPS Council on 8–9 June 2021, the member states agreed to text-based negotiations focusing on two proposals tabled by members. The members also decided to hold a series of meetings till the end of July 2021 to take stock of the text-based negotiations. However, the latest developments show that the waiver discussions hit a hurdle due to a split between the developed and developing countries over the negotiation text. This brief discusses how TRIPS becomes a barrier to the equitable access of COVID-19 vaccines. It also examines how a waiver will help India in its fight against COVID-19 at home and abroad. TRIPS and its Exceptions TRIPS, a comprehensive multilateral agreement on Intellectual Property (IP), was an outcome of the Uruguay Round (1986–94) of negotiations of the General Agreement on Tariffs and Trade (GATT). The Agreement came into force on 1 January 1995 and offers a minimum standard of protection for Intellectual Property Rights (IPR).6 In WTO, IPR are divided into two main categories. First, copyright and related rights (Articles 9 to 14, Part II of the TRIPS Agreement). Second, industrial property that includes trademarks, geographical indications, industrial designs, patents, integrated circuit layout designs, and undisclosed information (Articles 15 to 38, Part II of the TRIPS Agreement).7 Article IX.3 and IX.4 of the Marrakesh Agreement Establishing the WTO deals with TRIPS waivers. Article IX.3 says that in “exceptional circumstances” the Ministerial Conference may waive off an obligation imposed on WTO member countries.8 Such a decision requires the support of three-fourths of the WTO membership. According to Article IX.4, any waiver granted for more than one year will be reviewed by the Ministerial Conference. Based on the annual review, the Conference may extend, modify, or terminate the waiver. The TRIPS Agreement provides some flexibility primarily in the form of compulsory licensing and research exceptions through Articles 30 and 31. While Article 30 permits WTO members to make limited exceptions to patent rights, Article 31 provides a detailed exception, provided certain conditions are met. Compulsory licensing is the process of granting a license by a government to use a patent without the patent holder's consent. Article 31 permits granting compulsory license under circumstances such as “national emergencies”, “other circumstances of extreme urgency”, “public noncommercial use”, or against “anti-competitive” practices.9 In addition to these original waivers, the Declaration on the TRIPS Agreement and Public Health, adopted at the 2001 Doha Ministerial Meeting, also recognises some exceptions, for instance, in situations of a public health emergency, member countries have the freedom to determine the grounds upon which compulsory licenses are granted. Similarly, under Article 66.1, the least developed countries (LDCs) are given waivers for implementing TRIPS on pharmaceuticals till 1 January 2033. COVID-19 and TRIPS Waiver Two significant factors rekindled the debate on TRIPS waiver for essential medical products—first, vaccine inequity, and second, the insufficiency of existing waiver provisions in fighting the COVID-19 pandemic. COVID-19 is an exceptional circumstance, and equitable global access to the vaccine is necessary to bring the pandemic under control. However, the world is witnessing quite the reverse, i.e., vaccine nationalism. Vaccine nationalism is “my nation first” approach to securing and stockpiling vaccines before making them available in other countries. A TRIPS waiver would be instrumental in addressing the growing inequality in the production, distribution, and pricing of the COVID-19 vaccines. Vaccine Inequity According to Duke Global Health Innovation Center, which monitors COVID-19 vaccine purchases, rich nations representing just 14 per cent of the world population have bought up to 53 per cent of the most promising vaccines so far. As of 4 July 2021, the high-income countries (HICs) purchased more than half (6.16 billion) vaccine doses sold globally. At the same time, the low-income countries (LICs) received only 0.3 per cent of the vaccines produced. The low and middle-income countries (LMICs), which account for 81 per cent of the global adult population, purchased 33 per cent, and COVAX (COVID-19 Vaccines Global Access) has received 13 per cent.10 Many HICs bought enough doses to vaccinate their populations several times over. For instance, Canada procured 10.45 doses per person, while the UK, EU and the US procured 8.18, 6.89, and 4.60 doses per inhabitant, respectively.11 Source:“Tracking COVID-19 Vaccine Purchases Across the Globe”, Duke Global Health Innovation Center, Updated 9 July 2021. Consequently, there is a significant disparity between HICs and LICs in vaccine administration as well. As of 8 July 2021, 3.32 billion vaccine doses had been administered globally.12 Nonetheless, only one per cent of people in LICs have been given at least one dose. While in HICs almost one in four people have received the vaccine, in LICs, it is one in more than 500. The World Health Organization (WHO) notes that about 90 per cent of African countries will miss the September target to vaccinate at least 10 per cent of their populations as a third wave looms on the continent.13 South Africa, the most affected African country, for instance, has vaccinated less than two per cent of its population of about 59 million. This is in contrast with the US where almost 47.5 per cent of the population of more than 330 million has been fully vaccinated. In Sub-Saharan Africa, vaccine rollout remains the slowest in the world. According to the International Monetary Fund (IMF), at current rates, by the end of 2021, a massive global inequity will continue to exist, with Africa still experiencing meagre vaccination rates while other parts of the world move much closer to complete vaccination.14 This vaccine inequity is not only morally indefensible but also clinically counter-productive. If this situation prevails, LICs could be waiting until 2025 for vaccinating half of their people. Allowing most of the world’s population to go unvaccinated will also spawn new virus mutations, more contagious viruses leading to a steep rise in COVID-19 cases. Such a scenario could cause twice as many deaths as against distributing them globally, on a priority basis. Preventing this humanitarian catastrophe requires removing all barriers to the production and distribution of vaccines. TRIPS is one such barrier that prevents vaccine production in LMICs and hence its equitable distribution. TRIPS: Barrier to Equitable Health Care Access The opponents of the waiver proposal argue that IPR are not a significant barrier to equitable access to health care, and existing TRIPS flexibilities are sufficient to address the COVID-19 pandemic. However, history suggests the contrary. For instance, when South Africa passed the Medicines and Related Substances Act of 1997 to address the HIV/AIDS public health crisis, nearly 40 of world’s largest and influential pharma companies took the South African government to court over the violation of TRIPS. The Act, which invoked the compulsory licensing provision, allowed South Africa to produce affordable generic drugs.15 The Big Pharma also lobbied developed countries, particularly the US, to put bilateral trade sanctions against South Africa.16 Similarly, when Indian company Cipla decided to provide generic antiretrovirals (ARVs) to the African market at a lower cost, Big Pharma retaliated through patent litigations in Indian and international trade courts and branded Indian drug companies as thieves.17 Another instance was when Swiss company Roche initiated patent infringement proceedings against Cipla’s decision to launch a generic version of cancer drug, “erlotinib”. Though the Delhi High Court initially dismissed Roche's appeal by citing “public interest” and “affordability of medicines,” the continued to pressure the generic pharma companies over IPR. 18 Likewise, Pfizer’s aggressive patenting strategy prevented South Korea in developing pneumonia vaccines for children.19 A recent document by Médecins Sans Frontières (MSF), or Doctors Without Borders, highlights various instances of how IP hinders manufacturing and supply of diagnostics, medical equipment, treatments and vaccines during the COVID-19 pandemic. For instance, during the peak of the COVID-19 first wave in Europe, Roche rejected a request from the Netherlands to release the recipe of key chemical reagents needed to increase the production of diagnostic kits. Another example was patent holders threatening producers of 3D printing ventilators with patent infringement lawsuits in Italy.20 The MSF also found that patents pose a severe threat to access to affordable versions of newer vaccines.21 Source:“COVID-19 Vaccine R&D Investments”, Global Health Centre, Graduate Institute, Geneva, Updated 9 July 2021. The opponents of the TRIPS waiver also argue that IP is the incentive for innovation and if it is undermined, future innovation will suffer. However, most of the COVID-19 medical innovations, particularly vaccines, are developed with public financing assistance. Governments spent billions of dollars for COVID-19 vaccine research. Notably, out of $6.1 billion in investment tracked up to July 2021, 98.12 per cent was public funding.22 The US and Germany are the largest investors in vaccine R&D with $2.2 billion and $1.5 billion funding. Source:“COVID-19 Vaccine R&D Investments”, Global Health Centre, Graduate Institute, Geneva, Updated 9 July 2021. Private companies received 94.6 per cent of this funding; Moderna received the highest $956.3 million and Janssen $910.6 million. Moreover, governments also invested $50.9 billion for advance purchase agreements (APAs) as an incentive for vaccine development. A recent IMF working paper also notes that public research institutions were a key driver of the COVID-19 R&D effort—accounting for 70 per cent of all COVID-19 clinical trials globally.23 The argument is that vaccines are developed with the support of substantial public financing, hence there is a public right to the scientific achievements. Moreover, private companies reaped billions in profits from COVID-19 vaccines. Source: Katharina Buchholz, “COVID-19 Vaccines Lift Pharma Company Profits”, Statista, 17 May 2021. One could argue that since the US, Germany and other HICs are spending money, their citizens are entitled to get vaccines first, hence vaccine nationalism is morally defensible. Nonetheless, it is not the case. The TRIPS Agreement includes several provisions which mandates promotion of technology transfer from developed countries to LDCs. For instance, Article 7 states that "the protection and enforcement of IP rights should contribute to the promotion of technological innovation and the transfer and dissemination of technology, to the mutual advantage of producers and users of technical knowledge and in a manner conducive to social and economic welfare, and to a balance of rights and obligations."24 Similarly, Article 66.2 also mandates the developed countries to transfer technologies to LDCs to enable them to create a sound and viable technological base. The LMICs opened their markets and amended domestic patent laws favouring developing countries’ products against this promise of technology transfer. Another argument against the proposed TRIPS waiver is that a waiver would not increase the manufacturing of COVID-19 vaccines. Indeed, one of the significant factors contributing to vaccine inequity is the lack of manufacturing capacity in the global south. Further, a TRIPS waiver will not automatically translate into improved manufacturing capacity. However, a waiver would be the first but essential step to increase manufacturing capacity worldwide. For instance, to export COVID-19 vaccine-related products, countries need to ensure that there are no IP restrictions at both ends – exporting and importing. The market for vaccine materials includes consumables, single-use reactors bags, filters, culture media, and vaccine ingredients. Export blockages on raw materials, equipment and finished products harm the overall output of the vaccine supply chain. If there is no TRIPS restriction, more governments and companies will invest in repurposing their facilities. Similarly, the arguments such as that no other manufacturers can carry out the complex manufacturing process of COVID-19 vaccines and generic manufacturing as that would jeopardise quality, have also been proven wrong in the past. For instance, in the early 1990s, when Indian company Shantha Biotechnics approached a Western firm for a technology transfer of Hepatitis B vaccine, the firm responded that “India cannot afford such high technology vaccines… And even if you can afford to buy the technology, your scientists cannot understand recombinant technology in the least.”25 Later, Shantha Biotechnics developed its own vaccine at $1 per dose, and the UNICEF (United Nations Children’s Emergency Fund) mass inoculation programme uses this vaccine against Hepatitis B. In 2009, Shantha sold over 120 million doses of vaccines globally. India also produces high-quality generic drugs for HIV/AIDS and cancer treatment and markets them across the globe. Now, a couple of Indian companies are in the last stage of producing mRNA (Messenger RNA) vaccines.26 Similarly, Bangladesh and Indonesia claimed that they could manufacture millions of COVID-19 vaccine doses a year if pharmaceutical companies share the know-how.27 Recently, Vietnam also said that the country could satisfy COVID-19 vaccine production requirements once it obtains vaccine patents.28 Countries like the United Arab Emirates (UAE), Turkey, Cuba, Brazil, Argentina and South Korea have the capacity to produce high-quality vaccines but lack technologies and know-how. However, Africa, Egypt, Morocco, Senegal, South Africa and Tunisia have limited manufacturing capacities, which could also produce COVID-19 vaccines after repurposing. Moreover, COVID-19 vaccine IPR runs across the entire value chain – vaccine development, production, use, etc. A mere patent waiver may not be enough to address the issues related to its production and distribution. What is more important here is to share the technical know-how and information such as trade secrets. Therefore, the existing TRIPS flexibilities, such as compulsory and voluntary licensing, are insufficient to address this crisis. Further, compulsory licensing and the domestic legal procedures it requires is cumbersome and not expedient in a public health crisis like the COVID-19 pandemic.

2022 Michigan Negative
Turns › IPR Bad › 2NC---IPR Bad---Disease

Corporations are weaponizing patents.

Gubby, 19 [Helen Gubby works for Erasmus University, 9/26/19, accessed on 7-18-2022, Onlinelibrary.wiley, "Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective", https://onlinelibrary.wiley.com/doi/10.1111/1758-5899.12730]/ISEE

As the economy has largely shifted from industrial manufacturing to high-tech, life science and information processing industries, intellectual property has become more and more important. Corporations have become increasingly aware of the potential of the patent, not just as a shield to protect against imitation, but as a strategic tool to block competition and dominate markets. Patents have come to have a broader strategic function in which innovation may only play a small part. Although many patents do not produce any income: ‘In terms of strategy, though, the patent can be much more valuable’ (Macdonald, 2004, p. 143). Patent strategy is directly related to the business context. The Carnegie Mellon Survey of the US manufacturing sector in 1994 revealed that firms often used patents as strategic tools, rather than as simply a means of protecting an invention from wrongful imitation (Cohen et al., 2000). In their examination of motives to patent, Blind et al. (2009) recognised that, although protection from imitation was still the most important factor, ‘the importance of the strategic motives to patent are confirmed’ (Blind et al., 2006, p. 671). Patent strategies The decision to patent has become in part uncoupled from the original core purpose of the patent: to protect an invention from unfair imitation by other market participants. Larger firms, with the capital assets to pay for the cost of patenting, use their patent portfolios strategically. Patents have become useful as bargaining chips; they provide leverage. Large patent portfolios are a means to get access to important co-operations or cross-licensing arrangements (Blind et al., 2009, p. 431). Yet while building the portfolio requires enormous legal costs, it contributes little to research incentives. Furthermore, these portfolios can be used not just to oblige competitors to take licences, but also the terms of these licences can restrict competitors to certain areas of technology (Barton, 2000). Larger firms can afford to play the ‘wrap around’ strategy. Instead of applying for a single patent to cover an invention, other patents are filed around the main patent. These related patents lock down the discrete features of an invention. The tactic hinders entry to the market. Competitors will be put to time, effort and cost to fight their way through all the relevant patents covering the technology. Furthermore, the chance that the competitor's invention may infringe one of the many claims in one of the many patents is high. Not only can damages be awarded for infringement, but also an injunction. Injunctions prevent the party accused of infringement from producing any products that require the use of the technology covered by the infringed patent and all infringing products are removed from the market. Patents may be used simply to block competitors. Using a patent as a blocking strategy is common practice (Neuhäusler, 2012). Defensive blocking is used to protect a firm's own freedom to operate: it does not want to be shut out by the patents of its rivals. An offensive blocking strategy is where patents are filed to cover products or processes that the firm does not intend to practice itself, but which could be viable alternatives to competitors. By patenting all conceivable alternatives, research by competitors that might threaten their own technological lead can be thwarted. As in general a patentee is under no obligation to license out its technology to another, the strategy can deter market entry or new product launch. This offensive blocking of competitors by means of patents, ‘is clearly a case of the patent system being used for purposes other than for which it was originally intended’ (Blind, 2009, p. 436). However, both defensive and offensive blocking should be a policy concern, as they can reduce economic efficiency. Defensive patenting increases cost to firms without necessarily producing any benefit and offensive patenting can reduce technological progress and increase consumer costs by reducing competition (Thumm, 2004, p. 533). Using data from a large-scale survey of patent applications, Torrisi discovered that a substantial share of patents remained unused and a substantial number of patent applications were filed to block other patents. There were institutional differences; there were more unused patents in Japan and the EU than in the USA. Although cautious to make generalisations about unused patents, as some unused patents are there to ensure freedom to operate or simply because of management inefficiency, Torrisi et al. did conclude that: ‘[o]ur results highlight that there might be substantial benefits that patent owners draw from being able to keep patent rights unused. These would have to be balanced against possible harm imposed on other economic agents’ (Torrisi et al., 2016; , p. 1384). These strategies show a disconnect with the original purpose of the patent system. Patent strategies impact on innovation, and this in turn impacts on society. Concern was already expressed quite forcibly some years ago by Turner: Surely when the framers of the [US] Constitution empowered Congress to grant monopolies to ‘promote the progress of science and the useful arts’, they did not envision the beneficiaries of this grant would use it to bury new technologies to protect market share or capital investments. (Turner, 1998, p.209) Administrative failures Patent offices have been struggling to cope with the increasing number of patent applications: in 2017, more than 3 million patent applications were filed worldwide (WIPO, 2018). This influx has resulted in substantial application backlogs, with an increasingly long time between the patent filing and the patent grant: five years is not unusual. Complaints of poor quality control have been made concerning the US Patent and Trademark Office as well as the European Patent Office (Abbott, 2004; Mabey, 2010). The WIPO recognised a consistent upward trend in patent filings is putting patent offices under enormous pressure (WIPO, 2017, p. 13). Why are these administrative failings dangerous from a societal perspective? Patents grant a monopoly that can impact innovative processes for 20 years or more. Patents have been granted that should not have been granted. When an overly broad patent is granted, this can block further innovation by others. Broad patents may mean that access to vital research is not available because the results of that research are covered by patent claims. In particular, broad basic patents on fundamental research can block and deter follow-on research. The incentive to innovate is reduced (Barton, 2000; Henry and Stiglitz, 2010).1 Back in 1966, the societal implication of overly broad grants was expressed clearly by the US Supreme Court when it rejected a broad claim covering a group of chemicals: ‘Such a patent may confer power to block off whole areas of scientific development without compensating benefits to the public.’2

2022 Michigan Negative
Turns › IPR Bad › 2NC---IPR Bad---Disease

IPR’s hampers pharmaceutical innovation

Giovanni Dosi 21, Professor of Economics and Director of the Institute of Economics at the Scuola Superiore Sant'Anna in Pisa. He is the Co-Director of the task forces “Industrial Policy” and “Intellectual Property” at the Initiative for Policy Dialogue at Columbia University “Big pharma and monopoly capitalism: A long-term view”, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.,August 2021, https://www.econstor.eu/bitstream/10419/247295/1/2021-26.pdf)/maze

Abstract Are IPRs institutions meant to foster innovative activities or conversely to secure appropriation and profitability? Taking stock of a long-term empirical evidence on the pharmaceutical sector in the US, we can hardly support IPRs intended as an innovation rewarding institution. According to our analysis, pharma patents have constituted legal barriers to protect intellectual monopolies rather than an incentive and a reward to innovative efforts. Patenting strategies appear to be quite aggressive in extending knowledge borders and enlarging the space protected from the possibility of infringements. This is also witnessed by the fact that patent applications are very skewed in the covered trade names and patent thickness expands over time. Conversely, the number of patents protecting new drugs approved by the FDA which draw upon government-sponsored research – as such a mark for quality – falls. Firm-level analysis on profitability confirms strong correlation, restricted to listed pharmaceutical firms, between patent portfolio and profit margins.

1 Introduction Two distinctive roles have been attributed to intellectual property rights (IPRs hereafter) by the economic literature, namely, IPRs as incentives to undertake innovative activities and IPRs as forms of appropriation (Dosi, Marengo, and Pasquali 2006). As well acknowledged for instance by Adam Smith, Karl Marx and Joseph Schumpeter, just to mention the classics, expensive search efforts by profit-motivated agents imply some departure from purely competitive conditions. However, the two crucial issues concern, first, the extent of such a departure, that is the actual or expected extra-profit necessary to trigger innovative search, and, second, the possible monotonicity in the relation between such a departure and the intensity of innovative effort. Such questions are particularly thorny with respect to the scope and breadth of patents. In one perspective, which we may call the incentive view, patents, by restricting the possibility of imitation, grant the innovator a monopoly rent which should motivate ex-ante and compensate ex-post the R&D investment. In the alternative perspective, which we may call the opportunity view, innovative activities are primarily driven by the richness of opportunities of technological advances, while patents represent intellectual barriers to innovation and obstacles to its diffusion. Whether being institutional forms embraced to secure rents or to ensure legitimate profits, both streams recognize patents as creators of intellectual monopolies, even if in the former case they are a necessary evil to drive the “unbound Prometheus” of innovation in capitalist societies, while in the latter case they are primarily a mechanism of generation of unproductive rents. Among all sectors, the pharmaceutical one has been recognised to be one of the most dependent on patents in order to ensure its intellectual monopoly. The reliance of pharma on patents – it is commonly claimed – descends from the very nature of its production activity, based on very low reproduction costs, and facing instead almost exclusively entry costs in terms of knowledge generation. Given the potential easy replication of the knowledge embedded in a product (Dosi and Nelson 2010), patents ensure a temporary exclusive use of such knowledge which would instead be easily acquired by competitors. Additionally, the knowledge embedded into pharmaceutical patents is often discrete and might be well confined into claims, therefore quite apt to be patented (Orsenigo and Sterzi 2010). This work challenges the correspondence between patents and innovation. Let us start by noticing that historical records of drug search (see for instance the monumental history of drug discovery in Sneader (2005)) show that until very recently it has been mainly driven by search heuristics for discovery and experimentation very far from mere appropriation objectives, even when undertaken within corporate laboratories. More specifically, the modern pharmaceutical industry was born – mainly in Germany – under a regime of basically non-existent patent protection and then, after 1877, thrived under a regime of rather weak protection of processes rather than products. Still, the chemical/pharmaceutical oligopolies – later merged in 1925 into one monopolist firm, IG Farben1 – were able to reap hefty profits stemming from the integration of “pure” scientific research in close collaboration with universities, applied product-oriented research, industrialization and scaling-up of production, market penetration, and product diversification. At the turn of the 20th century, the leading German dyestuff companies were paying annual dividends between 18 and 26% (Plumpe 1991). The German chemical/pharmaceutical industry is the first one to enter the era of modern monopoly capitalism. We use this term as a shorthand to mean industrial regimes characterized by a) the visible hand (Chandler 1977) of either few oligopolistic firms, or indeed a monopoly like the one of IG Farben in 1920’s and 1930’s Germany, or of platform firms nowadays; and b) the ability of these oligopolists or monopolist to secure a sustained stream of differential profits/rents. Monopoly capitalism may be either due to complementary assets (Teece 1986) and distinct organizational capabilities (like those just mentioned with reference to the 19th century German chemical industry), or due to the consequences of the extreme increasing returns nature of information-intensive activities (such as those associated with the contemporary platform technologies), or due to the sheer outcome of monopolistic rights over crucial tangible or intangible assets such as patents.

2022 Michigan Negative
Turns › IPR Bad › 1NC---IPR Bad---Disease

Transnational Corporations create the conditions for disease.

Matthew Flynn 20, ,an Assistant Professor of Sociology and International Studies at Georgia Southern University in Statesboro, Georgia, “Global capitalism as a societal determinant of health: A conceptual framework”, Social Science & Medicine Volume 268, January 2021, 113530, 12-18-2020, https://www.sciencedirect.com/science/article/abs/pii/S0277953620307498)/maze accessed thru umich libraries

3.1. Transnational corporations The spread of TNCs contributes to uneven development regionally and globally, thereby increasing social inequality and the social gradient in health. Drastic trade openings or arrival of TNC operations can also generate economic instability, poverty, and population displacement (Labonté and Ruckert, 2019; Stiglitz, 2009). Corporate-driven factory closers and de-industrialization are associated with decreased life expectancy in the US since 2010 (Nosrati et al., 2018) and in Russia during the 1990s (Schrecker, 2014). Furthermore, Tausch, (2012) in a study of the health consequences of TNCs in 141 host countries, found that the degree of TNC penetration can temporarily boost growth but then has long-term negative consequences for equality, life expectancy, employment, and under-five mortality. TNCs operations have also found to have negative consequences for women's health, especially in export processing zones (Hippert, 2002; Shandra et al., 2010). Uneven development also results in the concentration of environmentally detrimental pollution. The agglomeration of heavy industries around shantytown areas exposes residents to heavy particulate matter, lead poisoning, and various forms of air pollution and toxic disposal (Auyero and Swistun, 2009). In rural areas, the global extractive industry adversely affects environmental health of entire communities, aside from offering precarious employment, and aggravating occupational health of workers (Schrecker et al., 2018). Indigenous communities like those in the Amazon basin are particularly vulnerable to oil spills, diseases spread by loggers, forced/violent displacement, and water contamination that lead to increased mortality, malnutrition, and sickness (Brisbois et al., 2019). Various economic interests also seek to corrupt science and information regarding the impact of their activities on global climate change that threaten the health of the planet. McMichael (2016) has detailed how TNCs play a determining role in how the global food regime impacts food security and nutrition. Agribusiness and financial interests have fueled a global land grab for industrialized agriculture that results in poverty, displacement, and informalization threatening food sovereignty. Industrialized food production not only involves indiscriminate antibiotic use that contributes to anti-microbial resistance and environmentally harmful application of pesticides and fertilizers, but global capitalism has led to a class divide between the wealthy who have healthier diet options and the rest dependent on mass-produced food of declining nutritional value (). Ecological pressures from global agribusiness lead to disease outbreaks (Wallace, 2020), while the expansion of TNCs into emerging markets has contributed to the growth of non-communicable diseases due to increased intake of unhealthy foods, alcohol, and tobacco (Freudenberg, 2014; Friel et al., 2015). At the point of delivery, the spread of fast-food chains offering cheap, ultra-processed foods, for example in China, are associated with rising obesity rates (Wang et al., 2016). There are also direct and indirect effects that TNCs have on health systems. For example, transnational drug companies provide essential inputs, but their operations result in increased social inequality and problematic access issues. High-value added basic research remains clustered around universities and research institutions, whereas clinical trials have been outsourced to the rest of the world with limited oversight regarding ethical concerns for human subjects and data quality (Homedes and Ugalde, 2014). By segmenting markets and using intellectual property laws, drug companies charge exorbitant prices that limit access to needed medicines, contribute to medical bankruptcies, threaten health system budgets, and increase deaths associated with adverse reactions (Light, 2020). Health insurers and managed care organizations have spread across the developing world to provide benefits to the upper and consuming classes, intensifying inequality, waste, and inefficiency (Homedes and Ugalde, 2005; Jasso-Aguilar et al., 2004). Indirectly, TNCs negatively impact tax revenues used to fund health systems and social programs through dubious accounting methods like corporate inversions, debt shifting, and transfer pricing. Not surprisingly, activists have targeted TNCs usurping natural resources, charging exorbitant prices on life-saving medicines, exploiting sweatshop labor, and creating ecological disasters. Bolivia's “Water Wars” is a case in point where popular mobilization of irrigation workers, farmers, teachers, factory workers, students, and others, organized strikes, blockades, referendum, and investigations that succeeded in putting a public water company under social control instead of a monopoly by Bechtal corporation (Waitzkin, 2018). Alternative economic arrangements such as the solidarity economy based on co-management, democratic decision-making beyond profit and state controls offers to protect worker's rights and health (Birn et al., 2017). In terms of health inputs, the non-profit collaboration Drugs for Neglected Disease initiative has six new treatments, 12 new molecular entities, and twelve clinical trials—all geared for public health—at a fraction of the cost reported by for-profit drug companies to develop medicines for public health goals (). Still, more work is needed to assess the various harmful impacts of TNCs, identify best strategies for changing corporate behavior, and implement policies mitigating their negative health impacts (Baum and Anaf, 2015).

2022 Michigan Negative
Defense › Emerging Tech › 1NC---Defense---Space Col

Space colonization is impossible.

Ekstrom '21 -doctor in astrophysics since 2008, specialising in stellar physics [Sylvai and Javier Nombela, Apr 7, "We will never live on Mars, or anywhere else besides Earth," https://www.swissinfo.ch/eng/we-will-never-live-on-mars--or-anywhere-else-besides-earth/46510576]

The human body has been shaped by millions of years of evolution on Earth. It is therefore perfectly adapted to an environment subject to a certain gravity and pressure value and protected from solar and galactic radiation by the dual protection of the Earth's atmosphere and magnetosphere. If it leaves this environment, it is subjected to great physiological stress.

The first problem is microgravity, which has many consequences:

2022 Michigan Negative
Defense › Emerging Tech › 1NC---Defense---Warming

We can’t stop warming.

Plumer '21 [Brad and Henry Fountain, Nov 11, "A Hotter Future Is Certain, Climate Panel Warns. But How Hot Is Up to Us," https://www.nytimes.com/2021/08/09/climate/climate-change-report-ipcc-un.html]

Humans have already heated the planet by roughly 1.1 degrees Celsius, or 2 degrees Fahrenheit, since the 19th century, largely by burning coal, oil and gas for energy. And the consequences can be felt across the globe: This summer alone, blistering heat waves have killed hundreds of people in the United States and Canada, floods have devastated Germany and China, and wildfires have raged out of control in Siberia, Turkey and Greece.

But that’s only the beginning, according to the report, issued on Monday by the Intergovernmental Panel on Climate Change, a body of scientists convened by the United Nations. Even if nations started sharply cutting emissions today, total global warming is likely to rise around 1.5 degrees Celsius within the next two decades, a hotter future that is now essentially locked in.

2022 Michigan Negative
Defense › Emerging Tech › 1NC---Defense---Disease

Pandemics won’t cause human extinction

Sebastian Farquhar 17. Director at Oxford's Global Priorities Project, Owen Cotton-Barratt, a Lecturer in Mathematics at St Hugh’s College, Oxford, John Halstead, Stefan Schubert, Haydn Belfield, Andrew Snyder-Beattie, 01-23-17, "Existential Risk Diplomacy and Governance", GLOBAL PRIORITIES PROJECT 2017, https://www.fhi.ox.ac.uk/wp-content/uploads/Existential-Risks-2017-01-23.pdf

1.1.3 Engineered pandemics For most of human history, natural pandemics have posed the greatest risk of mass global fatalities.37 However, there are some reasons to believe that natural pandemics are very unlikely to cause human extinction. Analysis of the International Union for Conservation of Nature (IUCN) red list database has shown that of the 833 recorded plant and animal species extinctions known to have occurred since 1500, less than 4% (31 species) were ascribed to infectious disease.38 None of the mammals and amphibians on this list were globally dispersed, and other factors aside from infectious disease also contributed to their extinction. It therefore seems that our own species, which is very numerous, globally dispersed, and capable of a rational response to problems, is very unlikely to be killed off by a natural pandemic. One underlying explanation for this is that highly lethal pathogens can kill their hosts before they have a chance to spread, so there is a selective pressure for pathogens not to be highly lethal. Therefore, pathogens are likely to co-evolve with their hosts rather than kill all possible hosts.39

2022 Michigan Negative
Defense › Emerging Tech › 1NC---Defense---Biod

Bio-d’s not existential and try-or-die is wrong. Nature’s a luxury, not a necessity.

Keim, 19—freelance journalist whose work has appeared in publications including The Atlantic, WIRED, National Geographic News, Aeon, Nautilus, Scientific American Mind, The Guardian, Audubon Magazine, Grist, Mother Jones, Conservation, NOVA, and Anthropocene (Brandon, “Conservation for the World We Want,” Breakthrough Journal, No. 11, Summer 2019, dml)

A slogan’s purpose, of course, isn’t to capture nuance. But there are ways in which this save-it-or-die framing rankles, beginning with the fact that, at precisely the same time as so many wild lives are imperiled, billions of people are enjoying historically unprecedented prosperity and health. That is not to say that economic well-being automatically flows from nature’s destruction, or that future well-being requires it, but simply that it has not yet precluded human flourishing.

Returning to megafauna and fire, Earth is more fire-prone than it once was, but people have managed — not without suffering, often with difficulty, but managed all the same. The depletion of whale populations and terrestrial megafauna reduced nutrient flows from the deep sea and across landscapes to a trickle, but the consequences were not catastrophic for us. Indeed, the state of nature that conservationists hope to protect, and present in terms of human self-interest, has already been radically transformed from just a few thousand years ago — not just because of the late Pleistocene mass extinctions, but also because of the dwindling of what and who remains.

2022 Michigan Negative
Defense › Geopolitics › 1NC---Defense---Democracy

Alt causes to democracy’s decline – it’s dead.

DeVega '22 - Senior politics writer for Salon [Chauncy, Mar 25, "How democracy dies: When it comes to Jan. 6, the American people can't handle the truth," https://www.salon.com/2022/03/25/how-democracy-dies-on-jan-6-the-american-people-cant-handle-the-truth/]

During my graveyard walks I have been thinking a great deal about America and its democracy crisis, and the poisons of fascism and white supremacy that are literally killing this country. I keep visualizing a tombstone with an inscription warning passers-by that most Americans didn't even fight for democracy while it was dying, but went on with life as usual. Those who tried to warn them about the impending disaster just got tired and gave up.

That is effectively happening right now, in real time. A recent article in the Washington Post issued a warning: "Jan. 6 committee faces a thorny challenge: Persuading the public to care." Apparently the House committee investigating the Capitol attack of January 2021 "has tried to recruit high-profile journalists to write its report ... hoping to build a narrative thriller that compels audiences and is a departure from government reports of yore." Committee staffers also hope "to put together blockbuster televised hearings that the public actually tunes into," which is a troubling way to frame a historic congressional investigation.

2022 Michigan Negative
Defense › Geopolitics › 1NC---Defense---Heg

Hegemonic decline inevitable – and no impact

McCoy '21 - J.R.W. Smail Professor of History at the University of Wisconsin-Madison [Alfred, Jan 29, "American Hegemony Is Ending With a Whimper, Not a Bang," ]

When empires decline and fall, they seldom collapse in the sort of sudden apocalypse portrayed in a monumental series of paintings entitled “The Course of Empire” by another denizen of the Catskill Mountains, the renowned artist Thomas Cole. His 1836 painting in that series, now appropriately enough hung at the Smithsonian Museum in Washington, shows a “savage enemy” plundering a grand imperial capital whose inhabitants, debased by years of luxurious living, can only flee in terror while women are raped and buildings burn.

Empires, however, usually experience a long, less dramatic decline before they fall in the Roman fashion, thanks to events whose logic only becomes apparent years or even decades later, as historians try to sort through the rubble. So it’s likely to be in what, until mid–last week, was (and still in many ways remains) Donald Trump’s America, where the signs of decline are as erratic as they are omnipresent.

2022 Michigan Counterplan
Aff › NB › 2AC – AT: RCA NB

Russia and China prevent Security Council effectiveness – NATO avoids

EL-Bawab, 4/26 (Nadine El-Bawab, 4-26-2022, "UN Security Council's inaction on Ukraine prompts questions on reform," ABC News, , LASA-CSK)

While experts said the U.N. facilitates diplomacy and keeps the lines of communication open between major powers, the Security Council's actions are tied to major powers' interests. The inequity of the Security Council is that nothing can be done if it opposes what the major powers want, Poast said. While the Security Council has not been able to pass any resolutions regarding the war in Ukraine or act to stop or prevent it, Poast said taking action is not part of its role. That is why NATO was created; to have a separate union, without China and Russia, allowing Western states to take action. "One of the big things that drove the process of creating NATO was the recognition sitting around late 1947 [to] 1948, that, from the British and the American perspective, they weren't going to be able to work with the Soviet Union," Poast said, adding that the powers needed a separate entity that would enable them to take action. Even in the early days of the U.N., Poast said there were concerns over whether the British, French and Americans would be able to work with the Soviets and Chinese. This was proven in 1999 when NATO took action in Kosovo, after the Security Council did not act, and again in 2011 when NATO intervened in Libya. "It's also a key reason why we're seeing NATO be very active in this war, because of exactly the fact that the U.N. Security Council has been ineffective in doing anything about this. But in contrast, NATO has been highly effective in trying to do something to support Ukraine," Poast said.

2022 Michigan Counterplan
Aff › NB › 2AC – AT: UN Good NB

P5 veto powser means nothing gets done

Koliward, 21 (Priya Koliwad, 10-06-2021, "Is the United Nations Still a Relevant International Body? — The World Mind ," World Mind, , LASA-CSK)

One of the arguments at the forefront in support for eliminating the United Nations is that the most powerful organ of the UN, the United Nations Security Council (UNSC), is not relevant to the modern world. The main evidence for this claim is that the UNSC only has five permanent member states: USA, Russia, Britain, China, France) and 10 non-permanent member states. This structure results in misuse of veto power, often blocking key decisions that are needed by nations with little to no representation. It also prevents developing countries from being represented, which is necessary in the present day.

Over the years, it has become clear that the Security Council’s permanent members have little interest in internal reform. Since this is the case, it is in the best interest of the other UN member states to continue to push for reform. With powerful countries moving to unilateralism, populism, and nationalism at the expense of multilateralism and collective action, a united and forward-looking Security Council capable of effectively driving the wider United Nations to achieve its goals is essential.

2022 Michigan Counterplan
Aff › NB › 2AC – AT: UN Good NB

The UN doesn’t have the scientific expertise to be effective

Juma, 2000 (Calestous Juma, Fall 2000, "The UN's Role in the New Diplomacy," Issues in Science and Technology, , LASA-CSK)

As a new form of international diplomacy develops to deal with a number of emerging issues in which science and technology play a central role, the United Nations (UN) risks being relegated to the sidelines. The influence and effectiveness of diplomats and international civil servants will increasingly depend on the extent to which they can mobilize scientific and technical expertise in their work. This need not require the UN to acquire extensive in-house scientific competence, but the organization–especially the office of the secretary general–must learn to tap advisory services to identify, mobilize, and use the best available expertise. Although a large number of UN agencies, programs, and treaties rely on scientific and technological expertise for their work, they are not designed to receive systematic science advice as a key component of effective performance. In most cases, science is used in the UN to support special interests and political agendas that do not necessarily advance the goals of the organization. But this should not come as a surprise. The UN was founded and grew to prominence in the era of the Cold War, when much of diplomacy was devoted to dealing with threats arising from external aggression. Today, attention is turning to issues such as infectious diseases, environmental degradation, electronic crimes, weapons of mass destruction, and the impacts of new technologies, which in the past would have been the concern of individual nations but have now grown to international stature. The UN’s capacity to deal with these questions must also grow. What is notable about the UN is that it includes organizations that cater to a wide range of jurisdictions but not to the growing community of science advisors. Even agencies such as the UN Educational, Scientific and Cultural Organization (UNESCO) have done little to provide a platform for the world’s science advisors. Specialized agencies such as UNESCO, the Food and Agriculture Organization, the World Health Organization, and the UN Industrial Development Organization relate to the UN secretary general’s office through a bureaucratic hierarchy that is not responsive to timeliness. They are generally accountable to their governing bodies and are heavily influenced by the interests of activist states. Even UN programs that deal with science-based issues such as the environment have yet to place knowledge at the core of their operations. They have failed to take into account the long-term implications of scientific advancement for their operations. Much of the attention in these programs is devoted to territorial aggrandizement and not to the role of knowledge in global governance. They are vestiges of Cold War institutional structures.

2022 Michigan Counterplan
Aff › NB › 2AC – AT: UN Good NB

UN charter outdated and ineffective in carrying out effective policy

Boothby, 99 (Derek Boothby, 07-14-1999, " NATO and the United Nations," No Publication, , LASA-CSK)

Personally, I doubt very much that the U.N. should ever be in the business of military peace enforcement. That is a task that should be carried out by fully effective military organizations, such as NATO or groups of states willing to do and capable of doing the job. Such organizations should first be given political license from the U.N. Security Council under Chapter VII; the operations should be halted if that political license is subsequently withdrawn. But the U.N. itself has neither the military command systems nor the political cohesion to carry out military-enforcement tasks. Moreover, it is arguable that a U.N. that carried out military peace enforcement--except perhaps in the most unique circumstances--would find itself in much political trouble with its members. In my view, Chapter VII of the U.N. Charter, as an authority for U.N. peace enforcement, was written for a different era and has little military application to today's world.

2022 Michigan Counterplan
Aff › Solvency › 1AR – Solvency – AT UN Bad Links to Aff

NATO doesn’t require UN oversight

Perry , 98 (James T. Perry, 1-1-1998, "," Naval War College Press, , LASA-CSK)

Chapter VIII of the UN Charter13 refers to regional organizations, such as NATO, in the context of appropriate regional action in the maintenance of international peace and security.14 It is in this area that a relationship exists between the two organizations, with ultimate authority centered in the United Nations. Excepting the area of international peace and security, however, the relationship between the UN and NATO is not hierarchical. When the NATO Charter was established in 1949 by the Treaty of Washington,15 it made no mention of any relationship to the Security Council as a "regional arrangement," nor did it contain any provision providing for action only upon the authorization of the Security Council, or for reporting activities "in contemplation." Instead, the Treaty of Washington expressed the obligation of NATO's member states to be that of "collective self,defense" under Article 51 of the UN Charter and, correspondingly, embodied only the obligation to report "measures taken" to the Security Council.16 This formulation was adopted by the United States and its NATO allies because subordination of NATO actions as a regional arrangement to Security Council review in advance during the Cold War would have subjected all actions to Soviet veto. By characterizing NATO's military actions as "collective self,defense" under Article 51, there would be no action of a "regional arrangement" under Chapter VIII of the UN Charter and no prior Security Council review.

2022 Michigan Counterplan
Aff › Solvency › 2AC – Solvency – Cyber

Empirics prove China and Russia block all UN attempts at cyberspace international law

Segal, 17 (Adam Segal, 6-29-2017, "The Development of Cyber Norms at the United Nations Ends in Deadlock. Now What?," Council on Foreign Relations, , LASA-CSK)

The prospects of developing norms of state behavior in cyberspace have been looking positively bleak recently. The Lazarus Group, which appears to have ties to North Korea, is suspected of being behind the WannaCry ransomware attacks that spread to 150 countries and hobbled the UK’s National Health Service. Russian hackers have been named as the culprits in the hacking of the Democratic National Committee (DNC), and are suspected of being responsible for blackouts in Kiev in 2015 and 2016. This week’s attack, Petya/NotPetyta, first looked like a new version of ransomware, but now seems designed for disruption and destruction. The attack appears to have originated in Ukraine, on the day before a holiday marking the 1996 adoption of that country’s first constitution, so early suspicion is that Moscow is behind the attacks, though this is still highly speculative (Russia itself has also suffered from Petya). Despite the proliferation of state-backed attacks, for a brief window, there did seem to be some forward movement on cyber norms. This week China and Canada agreed not to conduct cyber espionage for commercial gain against each other. Beijing has now signed similar agreements with the United States, United Kingdom, Australia, and the G-7 and G-20. In 2013, a group of government experts (GGE) at the UN agreed that international law, and especially the UN Charter, applies to state activity cyberspace. In 2015, the same group agreed to four peacetime norms promoted by the United States: states should not interfere with each other’s critical infrastructure; they should not target each other’s computer emergency response teams; they should assist other nations investigating cyberattacks; and they are responsible for actions that originate from their territory. That process seems to have reached a dead end. Last week, Michelle Markoff, deputy coordinator for cyber issues in the State Department published an explanation of the U.S. position at the end of the 2016-2017 GGE process. Markoff’s frustration is palpable, as she writes the current “report falls short of our mandate and doesn’t meets the standard that the previous GGEs have set for us.” The sticking point is the application of international law. The United States wanted to use the report to begin explaining exactly how international law applies in cyberspace, especially in the areas of the exercise of the inherent right of self-defense and the law of state responsibility, including countermeasures. Other participants argued that it was too early in the development of cyberspace to have such deliberations, and would in themselves be destabilizing. They would be “incompatible with the messages the Group should be sending regarding the peaceful settlement of disputes and conflict prevention.” Markoff does not call out the obstructionist states by name, but it is safe to assume China and Russia were among them. Beijing has never liked the idea that international law applies to cyberspace, and began walking back the 2013 report almost as soon as the ink was dry. Chinese officials have consistently stressed the UN Charter and the importance of sovereignty without mentioning the rest of international law. During the 2015 meeting of the UN group, China’s representative proposed taking out all references to international law in the upcoming report. In the wake of the DNC hack, Moscow would certainly not support discussions about countermeasures, which might cover U.S. reprisals for hacking and information operations.

2022 Michigan Counterplan
Aff › Solvency › 2AC – Solvency – Cyber

Perm solves – UN fails without the US pushing for cyber norms

Herman, 21 (Slate Herman, J.D. Candidate, University of Colorado Law School, 1-29-2021, "Cybersecurity and the U.N. Charter: A Square Peg in a Round Hole," Colorado Technology Law Journal, , LASA-CSK)

In this note I contend that the U.N. Charter fails to adequately address non-state actors or provide effective alternatives to armed conflict. The question of how to correctly classify these actions under international law then arises. Article 51 of the U.N. Charter imbues nations with the power of self-defense against an armed attack.[20] The ancient concept of an armed attack creates significant ambiguity when applied to the revolutionary concept of cyberwarfare. The use of armed forces and other similar definitions are inadequate in their understanding of cyberoperations. The U.N. Charter also fails to prescribe appropriate responses to cyber-attacks and splits appropriate action into two categories, neither of which allow cyber operations to be classified correctly. Current international law does not adequately address the growing problem of cyberwarfare. Specifically, the blind spots created by Articles 2(4), 41, 42, and 51 of the U.N. Charter in failing to address cyber warfare, coupled with lack of responsibility for non-state actors expose the United States to significant risk.[21] The United States must be active in pushing the U.N. to consider new regulations to fix these potholes in the U.N. Charter. Though some governmental bodies seem unwilling to join the discussion surrounding proper international cyberoperations, others leap headlong into the murky topic. The North Atlantic Treaty Organization (“NATO”) has taken the largest step to adequately define cyber operations and explain how international legal regimes apply to cyberweapons.[22] In 2009, the NATO Cooperative Cyber Defense Centre of Excellence embarked on a journey to produce a manual on the international law governing cyberwarfare, which became known as the Tallinn Manual.[23] The project collected distinguished practitioners and scholars in an attempt to project how current legal standards would govern this new form of warfare. With its primary focus on wartime action, the Tallinn Manual dives deeply into cyber operations involving the use of force and those that occur in the context of armed conflict.[24] In 2013, this text began serving as a resource for governments and scholars in the legal field.[25] Almost immediately after its publication, the group began work on a second edition of the Tallinn Manual. Released in February 2017, Tallinn 2.0 expanded on the original version and added multiple provisions while updating the original.[26] This manual serves as a background from which I make many of my assumptions and conclusions.

2022 Michigan Counterplan
Aff › Solvency › 2AC – Solvency – Biotech

UN biotech regulation wrecks developing countries widening the tech gap

Miller, 96 (Henry I. Miller, Robert Wesson Fellow of scientific philosophy & public policy, Hoover Institution Consulting Professor at the Institute for International Studies at Stanford University, 7-1-1996, "Biotechnology and the UN: New challenges, new failures," Nature, , LASA-CSK)

The overregulation of technology, though damaging to industrialized countries, is particularly devastating to developing countries because it acts as yet another, and formidable entry barrier to R&D. Thus, the UN's design's on biotechnology are likely to increase further the income gap between the "have" and "have not" nations, which more than doubled between 1960 and 1991. Poorly crafted regulatory proposals constitute a lose-lose proposition for the developing world. Virtually every field trial of every new biotechnology derived variant of rice, cassava, maize, wheat, sweet potato, or other plant would require an environmental assessment. These schemes would divert scarce resources to the regulation of activities that are largely of negligible risk, send inaccurate messages about risk to the public and to politicians, and impose a "tax" on innovation which is based on the excessively regulated techniques. These approaches also make new products artificially expensive to use, test, and produce: New crop plant varieties must be adapted to local conditions and the expense of testing them would become prohibitive. Thus, unnecessary case by case 834 review would diminish the degree and speed of technology diffusion to the developing world, developing countries would be prevented from participating in worldwide technological trends, and the technology gap that already exists between the industrialized and developing countries would widen further. There are bitter ironies in the demand that the developing world adopt unscientific, technique-based and anti-innovative regulatory approaches. First, the clamor usually originates from regulators or activists in industrialized countries who both regard Third-world regulation as an opportunity to validate their minority view of genetic engineering as manifesting unique risks and see prospects for becoming players on a larger stage. Second, such policies preferentially undermine research on precisely the kinds of low-value-added but important products that are most needed in developing countries- safer and more nutritious foods, improved bioremediation agents, and alternatives to chemical pesticides and fertilizers. At the same time, these poorly conceived policies exact a high cost, they are unlikely to afford any increment in environmental or public health protection